A Study to Investigate Health Related Quality of Life With a Pharmacist Intervention Compared to Treatment as Usual in Participants With Severe Mental Illness and Substance Use Disorder Receiving Treatment From FACT Teams. (pharmaFACT)
2026年5月13日 更新者:Anne Landheim、Sykehuset Innlandet HF
Optimizing Pharmacotherapy in Severe Mental Illness and Substance Use Disorder; Integrating a Clinical Pharmacist Into FACT Teams
The study aims to evaluate the impact of integrating a clinical pharmacist into Flexible Assertive Community (FACT) teams on health-related quality of life and pharmacotherapy for individuals with severe mental illness and substance use disorders.
This is a pragmatic effectiveness study using a stepped wedge cluster randomized trial design.
Four FACT teams from FACT Innlandet will serve as clusters, transitioning from standard care (control) to intervention in a randomized sequence.
The intervention involves integrating a clinical pharmacist into the interdisciplinary FACT teams.
Participants will be adults (over 18 years old), receiving treatment from participating FACT teams, diagnosed with severe mental illness or substance use disorder and prescribed at least one psychotropic medication.
Exclusion criteria include inability to provide informed consent, planned discharge within the first three months of period 1, or inability to communicate in Norwegian or English.
The control group receives standard care provided by FACT teams.
The intervention group will have a clinical pharmacist integrated into the FACT team performing medication reconciliation, comprehensive medication reviews, patient counselling, and interdisciplinary discussions to resolve medication-related problems.
A sample size of 160 patients is estimated based on an effect size of 0.25, 80% power and alpha=0.05.
The primary endpoint is change in patient-reported health related quality of life, measured using the EuroQoL-5 dimensions-5 levels (EQ-5D-5L) and Visual Analog Scale, EQ-VAS scores from baseline to the end of the intervention.
研究概览
研究类型
介入性
注册 (估计的)
160
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:LIv Marit Seljeflot
- 电话号码:+4799438311
- 邮箱:liv.marit.seljeflot@sykehuset-innlandet.no
研究联系人备份
- 姓名:Anne Signe Landheim, Professor
- 邮箱:anne.signe.landheim@sykehuset-innlandet.no
学习地点
-
-
-
Innlandet、挪威
- FACT
-
接触:
- LIv Marit Seljeflot
- 电话号码:+4799438311
- 邮箱:liv.marit.seljeflot@sykehuset-innlandet.no
-
首席研究员:
- Anne Signe Landheim, Professor
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Age over 18 years old
- Included in and receiving treatment from a participating FACT team
- Diagnosed with severe mental illness and/or substance use disorder
- Prescribed one or more psychotropic medication
- Signed informed consent
Exclusion Criteria:
- Patients not being competent or have the decision-making capacity to consent
- Planned discharge from the team within the first three months of period 1
- Patients not able to communicate in Norwegian or English
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:卫生服务研究
- 分配:随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:干涉
|
A clinical pharmacist will perform medication reconciliation, medication reviews and patient counselling.
其他名称:
|
|
无干预:Control phase
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Patient-reported health related quality of life
大体时间:EQ-5D-5L and EQ VAS will be assessed in period 1 (baseline (time 0-4 months), period 2 (4-8 months), period 3 (8-12 months), period 4 (12-16 months, period 5 (16-20 months) and period 6 (20-24 months).
|
Questionnaire EuroQoL EQ-5D-5L and EQ-VAS.
The results from the questionnaire EQ-5D-5L will be reported as a five digit health profile, an index value calculated using the Norwegian value set with a score between 0 and 1, where 0 is death and 1 is full health.
The EQ-VAS (visual analogue scale) is reported on a scale between 0-100 where 0 is worst imaginable health and 100 is best imaginable health.
|
EQ-5D-5L and EQ VAS will be assessed in period 1 (baseline (time 0-4 months), period 2 (4-8 months), period 3 (8-12 months), period 4 (12-16 months, period 5 (16-20 months) and period 6 (20-24 months).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in patient reported psychiatric burden
大体时间:The SCL-90-R will be assessed at control conditions and after completion of the pharmacist intervention per patient, estimated median of 2 months.
|
Questionnaire SCL-90-R.
The results from the questionnaire will be reported as a mean Global Severity Index between 0-4, where 0 is no reported symptoms and above 2 is severe distress.
|
The SCL-90-R will be assessed at control conditions and after completion of the pharmacist intervention per patient, estimated median of 2 months.
|
|
Change in patient reported attitudes towards pharmacological treatment
大体时间:The BMQ will be assesed at control conditions and after completion of the pharmacist intervention per patient, estimated median of 2 months.
|
Questionnaire Beliefs about medicines - BMQ. Results from the questionnaire will be reported as mean +/- standard deviation for each subscale.
Necessity-Concerns differential will be calculated, where a positive score indicates that perceived benefits outweigh conserns, a negative score indicates that concerns outweigh perceived benefits, and a score around zero indicates ambivalent beliefs.
|
The BMQ will be assesed at control conditions and after completion of the pharmacist intervention per patient, estimated median of 2 months.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:Jørgen Bramness, Professor、UiT The Arctic University of Norway
- 首席研究员:Anne Signe Landheim、Innlandet Hospital Trust Norway
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年5月1日
初级完成 (估计的)
2028年4月1日
研究完成 (估计的)
2031年2月1日
研究注册日期
首次提交
2026年4月30日
首先提交符合 QC 标准的
2026年5月13日
首次发布 (实际的)
2026年5月19日
研究记录更新
最后更新发布 (实际的)
2026年5月19日
上次提交的符合 QC 标准的更新
2026年5月13日
最后验证
2026年5月1日
更多信息
与本研究相关的术语
其他研究编号
- 2026_3597_
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.